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Abstract   22 
Setting: Hawassa Prison, Southern Region of Ethiopia.  23 
Objective: Determine the burden of pulmonary tuberculosis (TB) among incarcerated persons 24 
utilizing active case finding. 25 
Design: Cross sectional study.  Persons incarcerated were screened for TB using a symptom 26 
screen; those with a cough of ≥2 weeks had spot and morning sputum samples collected for AFB 27 
smear microscopy and molecular diagnostic testing (Xpert MTB/RIF). 28 
Results: Among 2068 prisoners, 372 (18%) had a positive cough screen. The median age of 29 
these 372 persons was 23 years, 97% were male and 63% were from urban areas. Among those 30 
with a positive symptom screen, 8 (2%) had a positive AFB sputum smear microscopy result and 31 
31 (8%) had a positive Xpert TB/RIF. The point prevalence of pulmonary TB at the prison was 32 
1748 per 100,000 persons. In multivariate analysis, persons with a cough >4 weeks were more 33 
likely to have TB (OR = 3.34, 95% CI 1.54-7.23).  34 
Conclusion: A high prevalence of TB was detected among inmates at a large Ethiopian prison. 35 
Active case finding using a cough symptom screen in combination with the Xpert had high 36 
utility and the potential to interrupt transmission of M. tuberculosis in correctional facilities in 37 
high burden, low- and middle-income countries.   38 
Key words: Active TB case finding, prison, Xpert MTB/RIF 39 
 40 
41 
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INTRODUCTION 42 
Tuberculosis (TB) disease burden is higher in prisons compared to the general population. 43 
Prisons are often neglected reservoirs for TB disease and can be significant amplifiers of disease 44 
both in prison and the community 1,2. Transmission of drug-resistant strains, overcrowding, poor 45 
living conditions, limited health care, inadequate TB treatment and control strategies, and high 46 
rates of HIV infection all contribute to the disproportional burden of TB in prisons 2. The World 47 
Health Organization (WHO) estimates 3 the prevalence of TB in prisons to be 10-100 fold higher 48 
than the general population. The median estimated fraction of TB in the general population 49 
attributable to the exposure in prisons for TB is 8.5%4.  50 
Globally, close to three million cases of active TB each year are undiagnosed by existing health 51 
systems 5, including many in the prison system, especially in sub-Saharan Africa 6,7. Lack of 52 
active surveillance and monitoring programs and well-equipped laboratory facilities for TB 53 
diagnosis contribute to low case finding among persons in prisons 8. Furthermore, overcrowding 54 
of prisons in low to middle-income countries provides a favorable environment for the 55 
transmission of Mycobacterium tuberculosis. In high burden TB countries, those who are 56 
incarcerated often come from underprivileged communities with higher risk and rates of TB 9.     57 
 58 
The impact of TB in prisons extends beyond prison walls into surrounding communities 10. 59 
Failure to control TB in prisons leads to enhanced TB transmission in the community, including 60 
drug-resistant disease 11. Thus, TB control in prisons is a major public health priority. However, 61 
there is limited understanding regarding TB epidemiology in African prisons. Previous studies 62 
carried out in African prisons reported 10 to 35 times higher TB prevalence in prisoners than in 63 
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the general population12-15. In many TB high burden settings in low and middle income 64 
countries, there is no effective TB control program in place in prisons.  65 
 66 
Ethiopia is among the high TB burden countries globally with an incidence rate of 192 per 67 
100,000 populations5. There are six Federal and 120 regional prisons and detention centers in 68 
Ethiopia 16. Most prisoners are incarcerated in an overcrowded and poorly ventilated 69 
environment. The health service in prisons is often poorly organized, lacks skilled manpower and 70 
laboratory facilities for TB diagnosis 4. Even though there is emerging prison TB prevention and 71 
control efforts in Ethiopia, it has been limited to a few prisons. Previous studies in the Ethiopian 72 
prisons reported point prevalence of TB ranging from 349 to 1913 per 100,000 populations2,17-23. 73 
However, there are no data on the burden of TB in Hawassa Prison one of the largest prisons in 74 
the Southern Ethiopia. Therefore, we aimed to estimate the burden of TB in this prison and 75 
assess the value of active TB case finding in a prison setting. 76 
 77 
Methods  78 
Study design/setting 79 
A cross-sectional study design was utilized to screen prison inmates for pulmonary TB as 80 
described below from June 15 through July 13, 2015and HIV serologic testing was offered from 81 
January 13 through February 10, 2016 at the Hawassa Prison, a regional prison in Southern 82 
Ethiopia. Hawassa Prison has a capacity of approximately 2,500 inmates and an average stay of 83 
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18 months per inmate. It has a clinic that provides general healthcare that performs sputum 84 
microscopy.  85 
 86 
Study population  87 
All prisoners without known TB were eligible to participate; informed consent was required for 88 
enrollment. Enrollment was performed by nurses from the prison clinic and prison’s health 89 
committee (prison inmates selected by prison authorities to facilitate health work between the 90 
inmates and the prison clinic). They provided study information to the prisoners by visiting their 91 
cells, asked those interested in participating to come to the prison clinic to receive further details 92 
about the study. All study participants had a cough screen performed and those with a positive 93 
screen (cough > 2 weeks) provided informed consent and were interviewed  including for the 94 
presence of other symptoms and asked to submit two sputum samples (1 spot and 1 morning). 95 
Five persons were already on anti-TB treatment and were excluded except for estimating point 96 
prevalence. We defined pulmonary tuberculosis (PTB) as prison inmates whose sputum sample 97 
were positive by Gene Xpert MTB/RIF assay.  98 
 99 
HIV screening was carried out after providing pre-counseling education by a trained prison 100 
nurse. Additionally, HIV testing was offered and performed for participants diagnosed with 101 
active TB cases after obtaining consent. 102 
 103 
Study variables 104 
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A structured questionnaire was used to collect patient demographics, history of prior TB 105 
treatment, incarceration history, tobacco and chat use based on self-report of prison inmates. 106 
 107 
Laboratory  108 
For each participant with a positive cough screen, spot and morning sputum samples were 109 
collected in the prison health clinic. AFB smear microscopy was done using regular light 110 
microscopy using Ziehl-Neelsen (ZN) technique 24. The remaining portions of the samples were 111 
transported daily to the regional public health laboratory that is about 500 meters far using ice. 112 
The two sputum samples were pooled into a single container and stored in -20 freezer until 113 
transport to Armauer Hansen Research Institute (AHRI) in Addis Ababa.   114 
External quality control was done for all the slides by an independently experienced laboratory 115 
technician at AHRI who was blinded to AFB microscopy and Xpert MTB/RIF results.   116 
The HIV screening was performed based on the national testing algorithm. In brief, blood 117 
samples from finger prick were tested first with HIV (1+2). Antibody Colloidal Gold (KHB), 118 
positive samples were confirmed with Stat-Pak while discordant results were resolved by HIV-119 
1/2 Unigold Recombinant assay.  120 
 121 
Data management 122 
All data were double entered into an online REDCap database 25 and analyzed using STATA v.1. 123 
In univariate analysis, differences in categorical variables were tested using the Chi-square test, 124 
and for continuous variables a two-sample t-test was used. A multivariable logistic regression 125 
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model was used to evaluate the independent association of potential risk factors with TB 126 
diagnosis. Model building and selection was based on the purposeful selection of covariates 127 
strategy as previously described, based on epidemiological findings in the univariate analysis and 128 
biological plausibility26.  A p-value of <0.05 was considered significant.  129 
 130 
Ethical consideration 131 
The study was approved by Addis Ababa University, AHRI Institutional Review Boards and the 132 
Ethiopian National Ethics Review committees. Study permission was also obtained from the 133 
Ethiopian Regional Health Bureau and prison administration. Patients with active TB started 134 
treatment in the prison clinic. Newly diagnosed HIV positive participants were linked to a nearby 135 
health institution providing HIV care.  136 
 137 
Results  138 
Among 2155 inmates, 2068 (98%) consented to participate and had a cough screen performed. 139 
From this group, 372 (18%) inmates reported a cough ≥ 2 weeks (Figure 1). Among those with a 140 
positive cough screen, the median age was 23 years (inter quartile range ([IQR] 20-28 years), 141 
362 (97%) were male and 10 (3%) were female. The majority of prisoners (n=329, 88%) had no 142 
prior history of imprisonment and most were from an urban area (n=235, 63%) (Table 1). There 143 
were 293 (73%) patients who reported having a fever, 315 (85%) night sweats and 241 (65%) 144 
weight loss. The median number of prisoners per cell was 162 ([IQR] 14 – 360) and the median 145 
duration of imprisonment at the time of screening was 10 months ([IQR] 0.5-2 years).  146 
 147 
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Pulmonary tuberculosis and HIV infection 148 
Among those with a positive cough screen, 8 (2%) had a positive AFB sputum microscopy and 149 
31 (8%) of 372 had a positive Xpert TB/RIF test results and thus had active pulmonary TB 150 
disease per our study definition. The results of the AFB sputum microscopy were concurred with 151 
the quality control readings at AHRI. All positive smear microscopy samples had a positive 152 
Xpert TB/RIF test. By considering the 5 PTB cases which were already on anti-TB treatment 153 
during the study period, the overall point prevalence of PTB at the prison was 1789 per 100,000 154 
persons. Among the 31 confirmed TB cases, 3 had a prior history of TB treatment. The median 155 
time in prison for TB cases was 8 months and the majority (n=19, 61.3%) had been imprisoned 156 
for ≤ 1 year; 28 (90%) were living with > 100 inmates per cell. One TB case with a prior history 157 
of TB treatment had rifampicin resistance detected by the Xpert and was confirmed as MDR TB 158 
by culture and drug susceptibility testing with resistance to isoniazid, rifampicin, streptomycin 159 
and ethambutol.  160 
 161 
For HIV screening, among2186 inmates incarcerated during the testing period, 2040 (93%) 162 
agreed to testing and nine (0.4%) were HIV seropositive. HIV testing was performed on 16 of 163 
the 31 inmates with pulmonary TB and none were positive.  164 
 165 
Predictors of PTB 166 
 167 
Duration of cough predicted TB in univariate analysis. In multivariate analysis, the presence of a 168 
cough > 4 weeks was independently associated with an increased risk of having PTB (OR = 169 
3.34, 95% CI 1.54-7.23) (Table 2).   170 
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 171 
Discussion  172 
Utilizing an active TB case finding strategy combining symptom screening and molecular 173 
diagnostic testing, we detected 31 previously undiagnosed cases of active pulmonary TB in a 174 
large Ethiopian prison. Along with the five known cases of TB, we found a TB prevalence of 175 
1789 per 100,000 in the prison population.  This prevalence is over 16 times higher than the 176 
prevalence found in the general Ethiopian population 27. Our results highlight the utility of active 177 
TB case finding utilizing a cough screen and Xpert RIF/MTB testing among high risk 178 
populations including persons incarcerated in prisons in a high TB burden country.   179 
 180 
The prevalence of TB at the Hawassa Prison was high despite a low HIV seroprevalence (0.4%) 181 
among those incarcerated. None of those persons found to have PTB in our study were HIV 182 
seropositive. The HIV prevalence among prison inmates in our study is lower than previous 183 
reports from the prisons in other areas of Ethiopia including Gondar (7.6%) 18, Tigray (4.4%) 21, 184 
and in 13 prisons in the country (4.4%) 20.  The lower prevalence of HIV infection in our study 185 
might reflect lower HIV prevalence in the southern region compared to other parts of Ethiopia 186 
28.Stigma in general is one of the major factors in hindering people from seeking health care 187 
services in the country, however, in the prison setting the acceptance rate for the HIV screening 188 
was high (93% agreed to HIV testing).  189 
 190 
Delays in diagnosis and incomplete treatment of TB are major challenges in most prison settings 191 
in resource-limited countries. These could be related to the limited availability of healthcare 192 
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services in the prisons and lack of TB diagnostics in many prison settings 8,11.  In many high 193 
burden, low and middle-income countries, TB control activities in prisons are not well integrated 194 
into national TB control programs 8, including in Ethiopia 16. In prison settings, the use of 195 
diagnostic tools with high sensitivity and specificity is recommended 29. Our study highlights the 196 
utility of active TB case finding that utilizes a rapid molecular diagnostic test.  Prior to our study, 197 
there was no ongoing surveillance for TB in the prison, and the only available diagnostic tool in 198 
the prison, AFB smear microscopy, was insensitive in our study and did not detect 75% of TB 199 
cases that were identified by Xpert MTB/RIF. Our study provides important data to support the 200 
an active TB case finding strategy that uses a cough symptom screen plus Xpert MTB/RIF in 201 
prison settings in order to increase the case detection, identify drug-resistant TB, and improve 202 
TB control activities by allowing separation of those with active PTB from other inmates. 203 
 204 
The prevalence of TB in the Ethiopian prisons has been reported to range from 349 to 1913 per 205 
100,000 prison populations 2,17-23. The observed PTB point prevalence in our study (1789 per 206 
100,000) was higher than reported from most previous Ethiopian studies 17-23 but within this 207 
range. The difference in the prevalence of TB in Ethiopian prisons could be due to the 208 
methodological differences employed in the studies for screening and diagnosis of cases, 209 
differing prevalence of HIV co-infection among those incarcerated in different regions and 210 
differences in the burden of the disease in the study areas. Studies conducted in the sub-Saharan 211 
African prisons also reported high prevalence of PTB ranging from 5.1% to 47.7% positivity 212 
13,30,31. The high prevalence of TB in prison settings can impact TB transmission in communities 213 
as well as prisons settings can amplify TB transmission and after release from prison, former 214 
inmates can transmit TB to contacts in the community 4,10.  215 
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 216 
Prisons can also be an important source of spread of drug-resistant TB 30 and high levels of MDR 217 
TB and XDR TB have been reported in prisons globally 8. In a study conducted in Zambia 14, 218 
resistance to at least one anti-TB drug was observed in 40 (23.8%) of cases and 16 (9.5%) were 219 
MDR-TB. Our study identified one case of rifampicin resistance TB using Xpert MTB/RIF test. 220 
This case was confirmed to be MDR TB by culture and drug susceptibility testing. A recent 221 
study 32also reported a 9.5% of MDR TB cases in Ethiopian prison settings. These findings 222 
highlighted the emergence of MDR TB in the prison settings and further emphasize the need for 223 
strengthening TB control activities in prison settings in Ethiopia. 224 
Our study was cross sectional in nature and thus not designed to determine the site of infection 225 
with M. tuberculosis (prison vs. community) among those found to have active TB disease.  The 226 
number of persons per cell was high and the median length of incarceration among those with 227 
TB was 10 months; 61% of those found to have TB by Xpert were incarcerated for ≤ 1 year. A 228 
study from a prison in Gondar, Ethiopia 18 reported that an incarceration range of 2-6 months 229 
was associated with TB positivity. Further studies are needed to further evaluate site of 230 
transmission and the impact of screening persons at the time of incarceration as an additional TB 231 
control measure.   232 
 233 
Limitations of the study 234 
This study is subject to some limitations. These include having HIV testing offered about 6 235 
months after TB screening rather than concurrently. Given the turnover in prisons, not all of 236 
those screened for TB were present when HIV testing was offered (and vice-versa). We relied on 237 
Xpert as the definitive diagnosis for TB rather than the gold standard of culture. Since the 238 
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sensitivity of culture is higher than Xpert among those that are smear negative, our findings may 239 
have underestimated the prevalence of PTB.  However, since culture is not widely available in 240 
many high TB burden, resource-limited countries including Ethiopia, use of Xpert is more 241 
feasible in many settings. Among the three TB cases that had a prior history of TB treatment, a 242 
culture was performed in only one of these cases (which is the MDR case in which the Xpert 243 
MTB/RIF identified rifampin resistance). Our approach of screening only symptomatic cases 244 
could underestimate the prevalence rate as asymptomatic or subclinical cases could be missed.  245 
 246 
Conclusion 247 
We found that active TB case finding which combined the use of a cough screen plus a 248 
commercially available molecular diagnostic test (Xpert) had high utility in detecting 249 
incarcerated persons with active PTB disease at a large prison in Ethiopia. Despite a low HIV 250 
seroprevalence among those incarcerated, the overall prevalence of PTB exceeded 1.7% of the 251 
prison population in Hawassa, Ethiopia. A cough >4 weeks was the only risk factor for TB 252 
identified among those with a positive symptom screen. Active TB case finding using a symptom 253 
screen in combination with Xpert has the potential to interrupt transmission of M. tuberculosis in 254 
correctional facilities in high burden, low and middle-income countries.  255 
 256 
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Figure 1. Study Diagram  363 
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Table 1. Predictors of having pulmonary TB among persons with a positive cough screen 374 
 375 
 376 
 377 
 378 
 379 
 380 
 381 
 382 
 383 
 384 
 385 
 386 
 387 
 388 
 389 
 390 
 391 
 392 
 393 
 394 
CI- confidence interval; OR-odd ratio; TB-tuberculosis 395 
a- p-value for Chi-square test unless otherwise stated;  b-p-value for two-sample t-test  396 
 397 
 398 
 399 
Characteristic 
 
 
Total (n=372 
(%)  
 
No TB 
(n=341) 
 
TB 
(n=31) 
Univariate analysis 
OR (95% CI) P- 
Valuea 
Sex (Male) 362 (97) 331 (97) 31 (100)   
Age (year), mean 26 26 24  0.08b 
Illiterate 322 (87) 294 (86) 28 (90) 1.49 (0.43-5.10) 0.52 
Unemployed  346 (93) 319 (94) 27 (87) 0.46 (0.14-1.44) 0.18 
Not married 209 (56) 192 (56) 17 (55) 1.06 (0.50-2.22) 0.87 
Duration of cough in 
weeks 
2- 4  
>4 
 
 
93(25) 
279 (75) 
 
 
78 (23) 
263 (77) 
 
 
15 (48) 
16 (52) 
 
 
 
3.16 (1.49-6.68) 
 
 
 
0.003 
Fever  273 (73) 247 (72) 26 (84) 1.97 (0.73-5.30) 0.17 
Night sweats 315 (85) 289(85) 26 (84) 0.93 (0.35-2.64) 0.89 
Loss of appetite    235 (63) 213 (62) 22 (71) 1.46 (0.65-3.28) 0.35 
Weight loss 241 (65) 219 (64) 22 (71) 1.36 (0.60-3.05) 0.45 
Chest pain 338 (91) 308 (90) 30 (97) 3.21 (0.42-24.3) 0.13 
Shortness of breath 252 (68) 228 (67) 24 (77) 1.69 (0.71-4.06) 0.23 
Previous imprisonment 43 (12) 42 (12) 1(3) 0.23 (0.03-1.78) 0.16 
Previous TB treatment 34 (9) 31 (9) 3 (10)  1.07 (0.30-3.72) 0.91 
Tobacco use (smoking 
cigarettes) at time of 
incarceration 
110 (30) 104(31) 6 (19) 0.54 (0.21-1.37) 0.19 
Chewing chat 171 (46) 159 (47) 12 (38) 0.72 (0.34-1.53) 0.39 
Incarceration period in 
years  
 ≤ 1 
 1-3 
>3 
 
 
180 (48) 
113 (30) 
79 (21) 
 
 
161 (47) 
106 (31) 
74 (22) 
 
 
19 (61) 
7 (23) 
5 (16) 
 
 
 
0.55 (0.22-1.37) 
0.54 (0.19-1.49) 
 
 
 
0.20 
0.28 
Contact with known TB 
patient in the prison 
 
90 (24) 
 
83 (24) 
 
7 (23) 
 
0.90 (0.37-218) 
 
0.82 
Presence of coughing 
people in the cell 
191(51) 175 (51) 16 (52) 1.01 (0.48-2.11) 0.97 
No. of prisoners per cell 
 ≤100 
 >100 
 
  
35 (9) 
337 (91) 
 
 
32 (9) 
309 (91) 
 
 
3 (10) 
28 (90) 
 
 
 
0.96 (0.27-3.35) 
 
 
 
0.95 
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Table 2. Multivariate analysis of predictors of pulmonary tuberculosis among prison inmates with a positive cough 400 
screen 401 
 402 
 403 
 404 
 405 
 406 
 407 
 408 
 409 
 410 
 411 
OR, odds ratio; CI, confidence interval  412 
 
 
Characteristics 
 
 
Multivariate analysis 
 
OR (95% CI) 
 
P- Value 
Duration of cough in 
weeks 
  
2-4  1.00  
>4 3.34 (1.54-7.23) 0.002 
Previous imprisonment 0.32 (0.04-2.50) 0.28 
Tobacco use 0.63 (0.24-1.64) 0.35 
Incarceration period in 
years  
  
≤ 1 1.00  
1-3 0.48 (0.19-1.23) 0.13 
>3 0.52 (0.18-1.51) 0.23 
